Another study showed that ivosidenib (AG-120) targeted IDH1 mutations could improve survival outcomes in participants with histologically confirmed IDH1-positive chemotherapy-refractory cholangiocarcinoma, with a PFS of 2.7 months (IQR 1.6-4.2) (21). Here, IDH1 is linked to cholangiocarcinoma.